Insider Selling: Electromed, Inc. (NYSE:ELMD) Director Sells 50,751 Shares of Stock

Electromed, Inc. (NYSE:ELMD) Director Andrew Summers sold 50,751 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.30, for a total transaction of $1,385,502.30. Following the transaction, the director now owns 65,714 shares in the company, valued at approximately $1,793,992.20. This trade represents a 43.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Andrew Summers also recently made the following trade(s):

• On Thursday, February 20th, Andrew Summers sold 35,273 shares of Electromed stock. The stock was sold at an average price of $28.83, for a total transaction of $1,016,920.59.
• On Wednesday, December 4th, Andrew Summers sold 12,731 shares of Electromed stock. The shares were sold at an average price of $29.98, for a total transaction of $381,675.38.
• On Monday, December 2nd, Andrew Summers sold 17,463 shares of Electromed stock. The stock was sold at an average price of $30.09, for a total transaction of $525,461.67.

Electromed Stock Performance

Electromed stock traded down $1.00 during trading hours on Monday, reaching $26.97. 153,045 shares of the stock were exchanged, compared to its average volume of 111,293. Electromed, Inc. has a 52-week low of $13.74 and a 52-week high of $35.56. The stock has a market cap of $230.78 million, a P/E ratio of 35.96 and a beta of 0.33. The firm’s 50 day moving average is $31.37 and its 200 day moving average is $25.49.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ELMD. Arrowstreet Capital Limited Partnership grew its holdings in Electromed by 261.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock worth $3,386,000 after acquiring an additional 82,839 shares during the period. Hunter Associates Investment Management LLC boosted its position in shares of Electromed by 12.3% during the 3rd quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock worth $2,199,000 after purchasing an additional 11,250 shares in the last quarter. Northern Trust Corp grew its stake in shares of Electromed by 14.1% during the 4th quarter. Northern Trust Corp now owns 65,350 shares of the company’s stock worth $1,931,000 after purchasing an additional 8,086 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Electromed in the 4th quarter valued at about $1,760,000. Finally, Susquehanna International Group LLP lifted its stake in shares of Electromed by 121.8% in the fourth quarter. Susquehanna International Group LLP now owns 56,726 shares of the company’s stock valued at $1,676,000 after purchasing an additional 31,148 shares during the period. 40.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on ELMD. B. Riley started coverage on Electromed in a research report on Thursday. They issued a “buy” rating and a $38.00 price target on the stock. StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.